Skip to main content

Mycoplasma Release Testing Cell and Gene Therapy Product Samples Containing Cells in 1 Hour using a Closed-System Next Gen PCR

Introduction

Testing for mycoplasma contamination is a required release test for Cell & Gene Therapy (CGT) products as specified in the major pharmacopeias(1-3). Current compendial methods require ≥ 28 days to generate results and are not suitable for short shelf-life products. Alternative nucleic acid test (NAT) methods are available and can reduce the time to result to hours instead of days.

The BIOFIRE® Mycoplasma test is a closed system sample-to-answer presence/absence NAT that is designed to detect over 130 mycoplasma  species in less than an hour. It requires minimal hands-on time and contains everything needed to run a molecular test. A closed system NAT lowers the risk of contamination and answers the needs of CGT manufacturers for a fast & easy Mycoplasma release test.

Currently, a double centrifugation sample preparation protocol (Figure 3A) has been validated as a release test following current regulatory guidelines with a Limit Of Detection (LOD) of ≤ 10 CFU/mL(4). Although, this protocol is compatible with a wide range of Bioproduction and CGT matrices(5), it  excludes mammalian cells and therefore does not align with the new draft European pharmacopeia (EP) guideline(6).

DOWNLOAD THE POSTER

Filename
Poster MYCOPLASMA RELEASE TESTING OF CELL AND GENE THERAPY PRODUCT SAMPLES CONTAINING CELLS - ISCT 2023.pdf
Size
1 MB
Format
application/pdf

    

Contact our experts today for more information on our Cell & Gene Therapy solutions.